Bevacizumab and Radiation Therapy for Sarcomas

Inclusion Criteria:

* Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration
* Tumor grade of intermediate or high grade
* Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis
* Primary tumors must be \> 5.0cm in maximal diameter and local recurrence can be any size
* 18 years of age or older
* Zubrod performance status of 0-2
* Adequate organ and marrow function

Exclusion Criteria:

* Metastatic disease
* Pregnant or lactating women
* HIV positive patients
* Prior treatment with radiation, chemotherapy or biotherapy for this tumor
* History or evidence of central nervous system (CNS) disease
* Serious, non-healing wound, ulcer, or bone fracture
* Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year
* History of stroke within the past 6 months
* Major surgical procedure or significant traumatic injury within 28 days
* Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents.
* Presence of bleeding diathesis or coagulopathy
* Proteinuria at baseline or clinically significant impairment of renal function
* History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months
* Documented history of uncontrolled seizures
* Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0
* Known history of deep vein thrombosis or pulmonary embolus
* Known hypercoagulable disorder
* History of hepatic cirrhosis or current hepatic dysfunction